Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $DNA #DNA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ginkgo Bioworks Holdings, Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

MELBOURNE, Australia and BOSTON, Nov. 17, 2021 /PRNewswire/ -- mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first step in the partnership, Ginkgo will establish an office in Melbourne in what is hoped to be a future long-term business expansion within Australia.

mRNA Victoria and Ginkgo Bioworks Announce Partnership to Grow the Bioeconomy & International Biosecurity Capabilities

Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q3 2021 Results - Earnings Call Transcript

BOSTON , Nov. 15, 2021 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), the leading horizontal platform for cell programming, today announced its results for the third quarter ended September 30, 2021. Please visit investors.ginkgobioworks.com  to view the update including a slide presentation with additional details on the third quarter and supplemental financial information, which will be posted following the call.

Ginkgo Bioworks Reports Third Quarter 2021 Results

New York, New York--(Newsfile Corp. - November 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...

GINKGO BIOWORKS INVESTOR ALERT Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their Options

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 12, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...

Ginkgo Bioworks Investor Alert

BOSTON, Nov. 11, 2021 /PRNewswire/ --  Ginkgo Bioworks  (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society.

Ginkgo Bioworks Launches Cell Development Kit Service for Standardized, Low-Cost Entry to its Cell Programming Platform

Synlogic

CAMBRIDGE, Mass. and BOSTON, Nov. 9, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the nomination of SYNB1353, an investigational Synthetic BioticTM medicine for the treatment of homocystinuria (HCU).

Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria

BOSTON, Nov. 8, 2021 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2021, on Monday, November 15, 2021, beginning at 8:00 a.m. ET. The presentation details and registration link will be available on Ginkgo's investor relations website at www.ginkgobioworks.com/investors and a replay will be made available.

Ginkgo Bioworks Announces Date of Third Quarter 2021 Results Presentation

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 5, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click...

Ginkgo Bioworks Shareholder Alert

Los Angeles, California--(Newsfile Corp. - November 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...

Ginkgo Bioworks Update

BOSTON, Oct. 27, 2021 /PRNewswire/ -- Arcaea (Ar-kay-uh), a company launched on the Ginkgo Bioworks (NYSE: DNA) Platform, today announced its $78M Series A to build a new, regenerative future for the beauty industry through expressive biology—where biology is used as a creative tool for self-expression. Arcaea will grow new ingredients and product experiences for beauty by leveraging technology such as DNA sequencing, biological engineering, and fermentation to activate unique storytelling.

Arcaea, a Company Launched on the Ginkgo Bioworks Platform, Announces $78M Series A To Build a New Foundation For the Beauty Industry through Expressive Biology

Selecta Biosciences

Selecta Biosciences Inc (NASDAQ: SELB) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases.  The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.

Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

BOSTON and WATERTOWN, Mass., Oct. 26, 2021 /PRNewswire/ -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to design novel and improved enzymes with transformative therapeutic potential to advance treatments for orphan and rare diseases.

Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases

Los Angeles, California--(Newsfile Corp. - October 25, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses To Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

Peloton

Spotify

Investment firm Baillie Gifford lowered exposure in Tesla Inc (NASDAQ:TSLA), Alibaba Group Holding (NYSE:BABA) and Nio Inc (NYSE:NIO) in the third quarter and snapped up shares in vaccine maker Moderna Inc (NASDAQ:MRNA) and Ginkgo Bioworks Holdings (NYSE:DNA) instead, regulatory filings reveal. What Happened: Baillie Gifford, a 110-year-old asset management firm and an early investor in Tesla, sold 1.99 million shares in the Elon Musk-led electric vehicle maker in the third quarter, reducing its holdings in the company by 12.5% from the previous quarter.

Baillie Gifford Trimmed Positions In Alibaba, Tesla, Nio, Moderna In Q3, Here's What It Bought Instead

A new project in the Lone Star state wasn't enough to convince the bears to hold on to their shares.

Why Shares of Ginkgo Bioworks Plunged Today

Los Angeles, California--(Newsfile Corp. - October 20, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

Quest Diagnostics

SECAUCUS, N.J. and IRVING, Texas and BOSTON, Oct. 20, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced it has formed an agreement with the Texas Department of State Health Services (DSHS) to provide COVID-19 Kindergarten through Senior (K-12) school testing services to support safer classroom learning throughout the state of Texas.

Quest Diagnostics to Provide K-12 School COVID-19 Testing in Collaboration with Ginkgo Bioworks to Support Safer Classroom Learning in Texas for New Statewide School Testing Program

BOSTON, Oct. 20, 2021 /PRNewswire/ -- Ginkgo Bioworks Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading horizontal platform for cell programming, announced today that management is scheduled to present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 3:00p.m. Eastern Time.

Ginkgo Bioworks Announces Participation in Jefferies Gene Therapy/Editing Summit

Today, a bullish analyst price target placed on Ginkgo Bioworks has sent DNA stock on a nice ride as investors pile into this growth play. The post Ginkgo Bioworks Price Predictions: Why One Analyst Thinks Hard-Hit DNA Stock Can Hit $14.50 appeared first on InvestorPlace.

Ginkgo Bioworks Price Predictions: Why One Analyst Thinks Hard-Hit DNA Stock Can Hit $14.50

Wall Street is waxing bullishly on this synbio start-up.

News for Ginkgo Bioworks Holdings Stock (DNA)